Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery

Castro, Beatriz; Reis, Ricardo dos; Cintra, Georgia; Sousa, Mileide Maria de Assunção; Vieira, Marcelo de Andrade; Andrade, Carlos Eduardo Mattos da Cunha

doi:10.1097/igc.0000000000001325

Cited by 21 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of TTC on the prognosis of patients with EOC undergoing CRS has already been described. However, while studies published to date frequently reveal a trend towards an impact on cancer specific survival [5,6,12,[14][15][16][17]22], significant results seem to be harder to demonstrate [18,[21][22][23]. Some studies which did not find any relationship between TTC and survival [24] included patients with macroscopic residual disease.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis of EOC is poor with a 5-year overall survival (OS) rate of under 50%. It is usually diagnosed at an advanced stage (i.e., stage III-IV according to the 2014 International Federation of Gynecology and Obstetrics (FIGO) classification), mainly due to the lack of an effective screening method and unspecific symptoms [2,[4][5][6][7]. Standard treatment for both early-and advanced-staged EOC consists of complete macroscopic cytoreductive surgery (CRS) followed by adjuvant platinumbased chemotherapy [2,4,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Rocher

Gaillard

Uzan

et al. 2021

JCM

View full text Add to dashboard Cite

To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36–56). The median OS was 77.2 months (65.9–106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months, p = 0.04). No impact on OS was found when TTC was below or above 6 weeks (78.5 and 66.8 months, respectively, p = 0.25). In the whole population, TTC had no impact on RFS or OS. None of the factors studied were associated with an increase in TTC. Chemotherapy should be initiated as soon as possible after CRS. A TTC greater than 8 weeks is associated with poorer OS in patients with advanced stage EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Rocher

Gaillard

Uzan

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…This suggests that downregulation of ITGA6 by MS13 could inhibit cell migration and invasion in AIPC cells. LAMA3 encodes laminins that are essential for the formation of the basement membrane and plays an additional role in regulating cell migration and mechanical signal transduction (Castro et al, 2018). Increased level of LAMA3 was reported in pancreatic ductal adenocarcinoma, ovarian and liver cancer (Svoboda et al, 2017;Zhang et al, 2019;Tang et al, 2019;Yang et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle–Apoptosis and PI3K Signalling Pathways

et al. 2021

View full text Add to dashboard Cite

Diarylpentanoids exhibit a high degree of anti-cancer activity and stability in vitro over curcumin in prostate cancer cells. Hence, this study aims to investigate the effects of a diarylpentanoid, 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one (MS13) on cytotoxicity, anti-proliferative, apoptosis-inducing, anti-migration properties, and the underlying molecular mechanisms on treated androgen-independent prostate cancer cells, DU 145 and PC-3. A cell viability assay has shown greater cytotoxicity effects of MS13-treated DU 145 cells (EC50 7.57 ± 0.2 µM) and PC-3 cells (EC50 7.80 ± 0.7 µM) compared to curcumin (EC50: DU 145; 34.25 ± 2.7 µM and PC-3; 27.77 ± 6.4 µM). In addition, MS13 exhibited significant anti-proliferative activity against AIPC cells compared to curcumin in a dose- and time-dependent manner. Morphological observation, increased caspase-3 activity, and reduced Bcl-2 protein levels in these cells indicated that MS13 induces apoptosis in a time- and dose-dependent. Moreover, MS13 effectively inhibited the migration of DU 145 and PC-3 cells. Our results suggest that cell cycle-apoptosis and PI3K pathways were the topmost significant pathways impacted by MS13 activity. Our findings suggest that MS13 may demonstrate the anti-cancer activity by modulating DEGs associated with the cell cycle-apoptosis and PI3K pathways, thus inhibiting cell proliferation and cell migration as well as inducing apoptosis in AIPC cells.

show abstract

“…Hypertension is a well-known risk factor for surgical complications in various surgeries, including breast reconstruction (31,32), joint replacement surgery (33)(34)(35), debulking cytoreductive surgery for ovarian cancer (36), and radical cystectomy (37). It has been also associated with increased anastomotic leaks after intestinal operation, including ileocolic anastomosis, esophagectomy, liver transplantation, and gastrectomy (38)(39)(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

Effects of antihypertensive drugs on surgical outcomes of breast reconstruction: a nationwide population-based claim study

Park

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Background: Experimental studies have reported that angiotensin receptor blockers (ARBs) increase the risk of surgical complications. However, clinical data on their effect on surgical outcomes are limited.The aim of this study was to investigate the impact of perioperative use of ARBs on the outcomes of breast reconstruction using population-based claim data.Methods: Data of patients who underwent direct-to-implant or abdomen-based autologous breast reconstruction after total mastectomy from April 2015 to December 2018 were obtained from the Health Insurance Review and Assessment Service database. The patients were categorized as ARB, non-ARB, control, and non-hypertension groups. The effects of ARBs on surgical complications, length of hospital stay, and complication-related medical costs were evaluated.Results: Of the 9,036 patients who met the inclusion criteria, 5,192 underwent direct-to-implant reconstruction, and 3,844 underwent abdomen-based autologous reconstruction. The length of hospital stay was the longest and the surgical complication rate and complication-related medical cost were the highest in the ARB group after both reconstruction methods. Compared with non-treatment with antihypertensive drugs, ARB use was found to be an independent risk factor for surgical complications in direct-to-implant reconstruction [odds ratio (OR), 1.96; 95% confidence interval (CI), 1.09-3.50; P=0.0237] and complicationrelated medical cost (OR, 1.93; 95% CI, 1.10-3.40; P=0.0221) in abdomen-based autologous reconstruction.Conclusions: Perioperative ARB use was associated with adverse postoperative breast reconstruction outcomes. These findings might have a significant impact on perioperative antihypertensive management; nevertheless, further studies are warranted to confirm the study findings.

show abstract

Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery

Abstract: Comorbidities and intraoperative bleeding are the most relevant findings related to surgical complications. Surgical approach (PDS or IDS) was not related with complications. Surgical complications were significantly related to ACD.

Cited by 21 publications

References 35 publications

Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group

Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle–Apoptosis and PI3K Signalling Pathways

Effects of antihypertensive drugs on surgical outcomes of breast reconstruction: a nationwide population-based claim study

Contact Info

Product

Resources

About